Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytosorbents Corporation - Common Stock (NQ:CTSO)

0.7820 +0.0001 (+0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytosorbents Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: CytoSorbents Q4 Earnings
 
Via Benzinga
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
 
Via Benzinga
Recap: CytoSorbents Q3 Earnings
 
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
A Preview Of CytoSorbents's Earnings
 
Via Benzinga
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and Dysfunction 
From CytoSorbents
Via GlobeNewswire
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Gold Moves Lower; US Crude Stocks Decline Last Week
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.27% to 37,758.26 while the NASDAQ rose 0.17% to 15,124.90.... 
Via Benzinga
Topics Stocks
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Crude Oil Down 1%; US Wholesale Inventories Fall In November
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points on Thursday. The Dow traded up 0.14% to 37,708.15 while the NASDAQ rose 0.19% to 15,127.17. The... 
Via Benzinga
Topics Stocks
Dow Gains 50 Points; US Jobless Claims Rise To 218,000
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 37,708.72 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
Company insiders participated in the transaction with $435,000 of investment 
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the 8th Annual Dawson James Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival 
From CytoSorbents
Via GlobeNewswire
Brady, America's Car-Mart And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
From CytoSorbents
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.